Pediatric uveitis is a topic of special interest not only because of the unique diagnostic and therapeutic challenges but also because of the lifetime burden of vision loss if the problem is not adequately treated, as well as the economic and psychological toll on the family. Often, uveitis in children is discovered as part of a routine eye exam; this silent, insidious inflammation can be difficult to treat and can lead to further complications if not handled skillfully. Corticosteroids have long been the mainstay of therapy; however, the significant associated side effects mandate a corticosteroid-sparing therapeutic regimen in pursuit of remission. In this review, we cover the therapeutic options for pediatric uveitis, specifically focusing on the most common non-infectious varieties, juvenile idiopathic arthritis-associated uveitis and pars planitis.

The hazard of chronic corticosteroid use for the treatment of adult, noninfectious uveitis is well-documented. Corticosteroid-sparing therapies, which offer a very favorable risk-benefit profile when administered properly, should be substituted.

There was a statistically significant decrease in the mean total area and number of lesions between the time of disease activity and disease quiescence (P < 0.01). Our results suggest that indocyanine green angiography has a role not only in diagnosis but also in monitoring treatment effectiveness; lesions can be reversible with treatment and their reappearance may be an indicator of disease relapse.

No abstract

Toxoplasmic retinochoroiditis is a clinical diagnosis which may be supported by positive serum immunoglobulin (Ig)M and/or IgG titers. Classically, it is manifested by necrotizing retinitis with secondary involvement of the choroid and vitreous. 1 New imaging modalities have aided in the diagnosis and management of intraocular inflammatory diseases. Optical coherence tomography (OCT) allows for micron-level resolution of the retinal and choroidal anatomy. Recent published OCT studies have described structural changes in the vitreous, retina, and choroid at the site of active toxoplasmosis lesions. 2 The purpose of this study was to determine whether the submacular choroidal thickness is also affected in cases of active cases of isolated, extramacular toxoplasmic lesions.The study protocol followed the Tenets of the Declaration of Helsinki and was approved by the local institutional review board. Written informed consent was obtained. Eyes with a history of vitreoretinal surgery, laser photocoagulation, intravitreal injections, refractive error exceeding AE4 diopters, or other retinovascular abnormalities were excluded.All patients completed a full ophthalmic evaluation including a dilated examination and imaging at each visit. All patients were